Compare Regeneron Pharmaceuticals Inc (REGN) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while iShares 10 20 Year Treasury Bond ETF trades at $92.19 (market cap $11.02B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.9× iShares 10 20 Year Treasury Bond ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares 10 20 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and iShares 10 20 Year Treasury Bond ETF for 60 Days on average.
| REGN | TLH | |
|---|---|---|
Market Cap | $76.14B | $11.02B |
Volume | 500,239 | 6,609,157 |
Sector | Health | Fixed Income |
52-Week High | $852.03 | $105.36 |
52-Week Low | $557.73 | $91.34 |
Typical Hold Time | 107 Days | 60 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.
The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.
TLH, an iShares 10-20 Year Treasury Bond ETF, trades at $92.19, up 0.81% on the day. The technical outlook is bearish based on moving averages, with neutral oscillators. Recent news highlights a challenging bond market environment, with Treasury yields reaching multi-decade highs, driving increased trading volume in the ETF. The fund continues its dividend distributions, with recent payments around $0.36-$0.38 per share.
The outlook for TLH is heavily influenced by the trajectory of long-term interest rates. Rising yields pressure bond prices, presenting headwinds, though the ETF offers income via dividends. Key risks include further Fed tightening and persistent inflation. Investors should weigh the income stability against potential capital depreciation in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
